Xbrane Pauses Primm Divestment Process
Halts Negotiations With Italy’s NewFaDem For Spherotide Triptorelin Developer
Executive Summary
Xbrane Biopharma has paused the process of divesting its Primm Pharma subsidiary, developer of the Spherotide long-acting triptorelin formulation, after failing to reach a final agreement with the expected acquirer, Italy’s NewFaDem.